Serve as the safety expert of the assigned product(s) within the Rare Disease portfolio
Establish the strategy, direction, and priorities of pharmacovigilance activities
Lead the Safety Analysis Team (SAT), Global Safety Team (GST) and is a core member of the Executive Safety Committee (ESC)
Validate safety signals and lead safety signal assessments
Develop and maintain Core Safety Information (core data sheet, core risks in informed consent forms, etc.)
Prepare/review core and regional risk management plans including additional risk minimization measures
Prepare/review safety sections of periodic aggregate reports
Provide safety input to protocols, statistical analysis plans, and clinical study reports
Prepare/review safety sections of new drug applications and other regulatory filings
Serve as safety expert on Evidence Generation Team for assigned products
Inspection Readiness
Domestic and International travel up to 10%
Requirements
MD or DO degree from an accredited medical school AND Completion of an accredited medical or surgical residency OR Clinical experience in either an accredited academic setting or private practice (including hospital based) setting
Product safety in the bio/pharmaceutical industry or regulatory agency
Expertise in Rare Disease therapeutic area, or clinical training
Experience with marketed product safety; risk management
Experience with phase 1-3 clinical trials safety assessments and analyses
Drug Submission experience
Leadership experience of the safety profile of products assigned with cross-functional team members.
Benefits
A comprehensive employee benefits package, including a Retirement and Savings Plan with generous company contributions
group medical, dental and vision coverage
life and disability insurance
flexible spending accounts
A discretionary annual bonus program, or for field sales representatives, a sales-based incentive plan
Stock-based long-term incentives
Award-winning time-off plans
Flexible work models, including remote and hybrid work arrangements, where possible